Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

Authors: Elizabeth England, D. Gareth Rees, Ian Christopher Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin D. Strain, Benjamin P. Kemp, Dominic J. Corkill, Richard D. May, Katherine A. Vousden, Robin J. Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen

Source: Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/4d1e1f2da3f148aa85e1df6a32f0ef69